Skip to main content
Clinical Trials/NCT03457090
NCT03457090
Unknown
Not Applicable

Extracorporeal Membrane Oxygenation and Cerebral Blood Flow Velocity Evaluated by Transcranial Doppler

University Hospital, Toulouse1 site in 1 country30 target enrollmentApril 5, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Extracorporeal Membrane Oxygenation Complication
Sponsor
University Hospital, Toulouse
Enrollment
30
Locations
1
Primary Endpoint
Cerebral blood flow velocities evolution
Last Updated
8 years ago

Overview

Brief Summary

To determine how venoarterial extracorporeal membrane oxygenation (ECMO) affects cerebral blood flow velocity (CBFV) measured by transcranial doppler (TCD), to determine whether specific changes in cerebral blood flow velocity may be associated with neurologic injury and to determine modifications of CBFV after withdrawal of ECMO.

Detailed Description

Venoarterial Extracorporeal membrane oxygenation (ECMO) is used in adult with refractory cardiac failure as a life-saving measure. Adults treated with ECMO survived to hospital discharge in 21,8% to 65,4% of cases. Neurologic complications such as intracranial hemorrhage, anoxia and ischemia are major causes of death and long-term disability in ECMO patients (7% to 14%). Current neurological monitoring techniques are insufficient to predict which critically ill patient receiving ECMO therapy will suffer from neurologic injury. Even after a clinical suspicion of neurologic injury, diagnosis can be difficult. TCD is commonly used to monitor the CBFV of traumatic brain injury. There are no reports that evaluate CBFV of patients requiring ECMO therapy. Patient will have to do both echocardiography and TCD to evaluate cardiac output and CBFV. We will repeat these dopplers every 24 hours until ECMO withdrawal and one day after explantation.

Registry
clinicaltrials.gov
Start Date
April 5, 2018
End Date
September 2020
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • adult patient who receiving ECMO therapy

Exclusion Criteria

  • cervico-encephalic vasculopathy
  • lacked an acoustic window allowing for adequate TCD examination
  • stroke in medical past.

Outcomes

Primary Outcomes

Cerebral blood flow velocities evolution

Time Frame: 24 hours

Cerebral blood flow velocities evolution over the time

The correlation of Cerebral blood flow velocities with the variation of the cardiac output and ECMO flow.

Time Frame: 24 hours

The correlation with the variation of the cardiac output and ECMO flow.

Secondary Outcomes

  • Relation between acute neurologic injury and variation of CBFV(24 hours)
  • Modification of the CBFV detected by TCD after the withdrawal of the ECMO.(24 hours)
  • Relation between the CBFV, the NIRS, the cardiac flow and the ECMO flow.(24 hours)

Study Sites (1)

Loading locations...

Similar Trials